Impact of post-progression survival in second-line treatment with molecular target agents for unresectable hepatocellular carcinoma.

PPS plays a more significant role than PFS in extending OS in patients given second-line treatment for unresectable HCC. Sequential therapies after disease progression in second-line treatment are essential to acquire good OS. Maintenance of hepatic reserve function and the patient's general condition is essential during systemic treatments for unresectable HCC. This article is protected by copyright. All rights reserved.